![Monika A. Vnuk](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Monika A. Vnuk
Directeur Général chez
Ignite Immunotherapy, Inc.
Profil
Monika A. Vnuk is currently the Chief Executive Officer at Ignite Immunotherapy, Inc. Prior to her current position, she held various roles including Treasurer & Director at BioNJ, Inc., Director at Vivet Therapeutics SAS, Managing Director at Blackstone Life Sciences Advisors LLC from 2021 to 2023, and Vice President-Worldwide Business Development at Pfizer Inc. from 2018 to 2021.
She also worked as an Associate at Oxford Bioscience Partners.
Dr. Vnuk obtained her undergraduate and doctorate degrees from Boston University in 1996 and 2000 respectively.
Postes actifs de Monika A. Vnuk
| Sociétés | Poste | Début |
|---|---|---|
Ignite Immunotherapy, Inc.
 Ignite Immunotherapy, Inc. BiotechnologyHealth Technology Designs and develops oncolytic virus vaccines | Directeur Général | - |
Anciens postes connus de Monika A. Vnuk
| Sociétés | Poste | Fin |
|---|---|---|
Blackstone Life Sciences Advisors LLC
 Blackstone Life Sciences Advisors LLC Investment ManagersFinance Blackstone Life Sciences invests in companies located across the globe. The firm targets companies operating in the fields on pharmaceutical, biotechnology and medical technology sectors. It provides financing for growth stage transactions. | Private Equity Investor | 01/01/2023 |
| PFIZER INC. | Corporate Officer/Principal | 01/06/2021 |
Oxford Bioscience Partners
 Oxford Bioscience Partners Investment ManagersFinance Oxford Bioscience Partners (OBP) focuses on investments in emerging, entrepreneurial-driven companies in the life sciences and healthcare sectors. They look for companies in the medical devices, R&D instruments and systems and therapeutics industries and for companies with breakthrough life sciences technology. The firm also invests in non-life science based technologies that have novel healthcare applications. OBP considers investments at almost any stage, but they place emphasis on early-stage opportunities. Investments range from $1 million to $10 million, but they may also make smaller seed investments in certain situations. OBP acts as the lead investor to organize an appropriate syndicate of co-investors. They consider investments in almost all geographic locations. | Analyste en capital-investissement | 31/12/2005 |
BioNJ, Inc.
 BioNJ, Inc. Miscellaneous Commercial ServicesCommercial Services Promotes the biotechnology industry in New Jersey | Directeur/Membre du Conseil | - |
Vivet Therapeutics SAS
 Vivet Therapeutics SAS BiotechnologyHealth Technology Operates as a clinical-stage emerging biotechnology company that develops novel gene therapy treatments for rare and inherited metabolic diseases | Directeur/Membre du Conseil | - |
Formation de Monika A. Vnuk
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
98
Relations au 1er degré
7
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Pfizer Inc.
 Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
Oxford Bioscience Partners
Oxford Bioscience Partners Investment ManagersFinance Oxford Bioscience Partners (OBP) focuses on investments in emerging, entrepreneurial-driven companies in the life sciences and healthcare sectors. They look for companies in the medical devices, R&D instruments and systems and therapeutics industries and for companies with breakthrough life sciences technology. The firm also invests in non-life science based technologies that have novel healthcare applications. OBP considers investments at almost any stage, but they place emphasis on early-stage opportunities. Investments range from $1 million to $10 million, but they may also make smaller seed investments in certain situations. OBP acts as the lead investor to organize an appropriate syndicate of co-investors. They consider investments in almost all geographic locations. | Finance |
Boston University
 Boston University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BioNJ, Inc.
BioNJ, Inc. Miscellaneous Commercial ServicesCommercial Services Promotes the biotechnology industry in New Jersey | Commercial Services |
Vivet Therapeutics SAS
Vivet Therapeutics SAS BiotechnologyHealth Technology Operates as a clinical-stage emerging biotechnology company that develops novel gene therapy treatments for rare and inherited metabolic diseases | Health Technology |
Blackstone Life Sciences Advisors LLC
Blackstone Life Sciences Advisors LLC Investment ManagersFinance Blackstone Life Sciences invests in companies located across the globe. The firm targets companies operating in the fields on pharmaceutical, biotechnology and medical technology sectors. It provides financing for growth stage transactions. | Finance |
Ignite Immunotherapy, Inc.
Ignite Immunotherapy, Inc. BiotechnologyHealth Technology Designs and develops oncolytic virus vaccines | Health Technology |
